Urovant Sciences

Urovant Sciences is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for urological diseases. Urovant's primary therapeutic candidate is vibegron (RVT-901), an investigational oral β3-adrenergic agonist for the treatment of overactive bladder with symptoms of urgency urinary incontinence, urgency, and frequency.